NCT05469802

A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults

A Randomized, Observer-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Immunogenicity of the Purified Inactivated Zika Virus Vaccine (PIZV) Administered on Days 1 and 29 in Healthy Participants Aged 18 to 49 Years in the US

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Takeda · Industry
• Sex: All
• Age: 18 Years – 49 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to describe the side effects and immune response of a candidate vaccine that might protect against Zika. The vaccine called PIZV (purified inactivated Zika virus vaccine) is given by injection in two doses that are 28 days apart in healthy adults. Participants will receive PIZV or placebo and will be followed for 7 days after each dose and up to 6 months after dose 2.

Detailed description

The candidate vaccine being tested in this study is called PIZV (purified inactivated zika virus vaccine) or TAK-426. This study will look at the safety and immunogenicity of PIZV in healthy participants. The study will enroll approximately 78 healthy participants (≥18 to 49 years) following a 2-dose vaccination schedule. Participants will be randomly assigned (by chance, like flipping a coin) in a 2:1 ratio to either PIZV or placebo which will remain undisclosed to the study observer during the study: * PIZV * Placebo Participants will receive PIZV or placebo 0.5 mL intramuscular (IM) injection into the middle third of the deltoid muscle, preferably in the non-dominant arm on Days 1 (Visit 1) and 29 (Visit 3). The seropositivity rate, seroconversion rate, and geometric-mean titers will be measured 28 days post dose 2. Solicited local reactions and systemic adverse events (AEs) will be assessed for 7 days after each vaccination. Unsolicited AEs will be assessed for 28 days after each vaccination and serious AEs (SAEs), AEs of special interest (AESIs), medically-attended AEs (MAAEs), and AEs leading to withdrawal from the trial throughout the entire study period. This multi-center trial will be conducted in the United States (US). Trial participants will be in this study for 7 months.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
BIOLOGICAL	Purified Inactivated Zika Virus Vaccine (PIZV)	PIZV vaccine with aluminium hydroxide adjuvant IM injection.
OTHER	Placebo	Placebo (normal saline (0.9% NaCl) IM injection.

Timeline

• Start date: 2024-01-02
• Primary completion: 2024-07-05
• Completion: 2024-07-05
• First posted: 2022-07-22
• Last updated: 2024-03-13

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study